Clinical Trials Browser

Completed × INDUSTRY × tislelizumab × Clear all

NCT04164199 2026-06-03

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Phase 3 Completed

Advanced Malignancies

NCT06010303 2026-05-28

A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Phase 2 Completed

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT05519865 2026-04-20

A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT03957590 2026-04-13

A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma

Phase 3 Completed

370 enrolled 17 charts

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT03744468 2026-04-02

Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors

Phase 1/2 Completed

147 enrolled 74 charts

Head & NeckOther solid neoplasmThoracic

Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in

NCT05516914 2026-04-01

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

Phase 1/2 Completed

Neoplasms

NCT04282018 2026-02-20

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

Phase 1/2 Completed

97 enrolled 43 charts

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05116085 2026-02-13

Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer

Phase 2 Completed

33 enrolled 11 charts

Gastrointestinal

Colorectal Neoplasms

NCT05577702 2026-02-09

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

Phase 2 Completed

121 enrolled 25 charts

Carcinoma, Non-Small-Cell Lung

NCT03412773 2025-10-14

A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)

Phase 3 Completed

684 enrolled 43 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT04215978 2025-10-03

Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Phase 1 Completed

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT05014815 2025-09-16

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

Phase 2 Completed

272 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT05267054 2025-09-15

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

Phase 1/2 Completed

53 enrolled 17 charts

Lymphoma, Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT05014828 2025-08-24

To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors

Phase 2 Completed

58 enrolled 16 charts

Other solid neoplasm

Advanced Solid Tumor

NCT04047862 2025-08-22

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Phase 1 Completed

446 enrolled 49 charts

Other solid neoplasm

Locally Advanced and Metastatic Solid Tumors

NCT03783442 2025-07-29

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Phase 3 Completed

649 enrolled 22 charts

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04693234 2025-04-27

AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer

Phase 2 Completed

178 enrolled 26 charts

Uterine Cervical Neoplasms

NCT04716634 2025-03-25

Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors

Phase 2 Completed

84 enrolled 17 charts

Other solid neoplasm

Advanced Solid Tumors

NCT04401800 2025-03-10

Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma

Phase 2 Completed

64 enrolled 23 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT04005716 2025-02-28

Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

Phase 3 Completed

457 enrolled 20 charts

Small Cell Lung Carcinoma

NCT04666688 2025-02-12

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Completed

GastrointestinalGenitourinaryHead & Neck

Bile Duct Neoplasms, Carcinoma, Transitional Cell, Colonic Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03358875 2025-02-10

RATIONALE-303

Phase 3 Completed

805 enrolled 26 charts

Carcinoma, Non-Small-Cell Lung

NCT03663205 2025-02-04

A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer

Phase 3 Completed

334 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT03924986 2025-01-31

RATIONALE-309

Phase 3 Completed

263 enrolled 19 charts

Nasopharyngeal Neoplasms, Recurrence

NCT04732494 2025-01-31

AdvanTIG-203

Phase 2 Completed

125 enrolled 25 charts

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04276493 2024-12-06

Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

Phase 1/2 Completed

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT03666143 2024-11-04

A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Phase 1 Completed

216 enrolled 20 charts

Other solid neoplasm

Advanced Solid Tumors

NCT03419897 2024-10-26

Study of BGB-A317 in Participants With Previously Treated Unresectable HCC

Phase 2 Completed

249 enrolled 24 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT03430843 2024-10-26

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Phase 3 Completed

512 enrolled 27 charts

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis

NCT03493451 2024-10-26

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Phase 2 Completed

77 enrolled 20 charts

DermatologicLymphoid

Immunoblastic Lymphadenopathy, Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell

NCT03594747 2024-10-26

A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer

Phase 3 Completed

360 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT03941873 2024-10-26

A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer

Phase 1/2 Completed

111 enrolled 22 charts

Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular

NCT04004221 2024-10-26

Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer

Phase 2 Completed

113 enrolled 15 charts

Locally Advanced or Metastatic Urothelial Bladder Cancer

NCT04068519 2024-10-26

Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody

Phase 1/2 Completed

300 enrolled 23 charts

Other solid neoplasm

Advanced Solid Tumors

NCT04952597 2024-10-26

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

Phase 2 Completed

126 enrolled 19 charts

Limited Stage Small Cell Lung Cancer

NCT03432598 2024-10-23

Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer

Phase 2 Completed

Lung Neoplasms

NCT03469557 2024-10-23

BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma

Phase 2 Completed

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Stomach Neoplasms

NCT05508100 2024-05-24

Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumor

NCT02795182 2022-07-01

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

Phase 1 Completed

75 enrolled 17 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Recurrence

NCT02660034 2021-12-06

The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

Phase 1 Completed

229 enrolled 46 charts

Other solid neoplasm

Solid Tumors

NCT02407990 2021-11-17

Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors

Phase 1 Completed

451 enrolled 42 charts

Advanced Cancer